CD8A and neoplasm: Modified OV therapy has demonstrated an enhanced anti-tumor effect on CD8+ T cells, leading to increased infiltration of effector CD8+ T cells into tumors and establishment of memory CD8+ T cells, while concurrently reducing associated depletion of CD8+ T cells (20).